经导管植入125I放射性粒子治疗肝癌伴门静脉癌栓的效果

Effect of transcatheter implantation of 125I radioactive seeds in the treatment of hepatocellular carcinoma with portal vein cancer thrombus

目的探讨经导管植入125I放射性粒子治疗肝癌伴门静脉癌栓的效果。方法选取2016年3月~2018年3月江西省湘雅萍矿合作医院收治的40例肝癌伴门静脉癌栓患者作为研究对象,按照治疗方式不同将其分为对照组(20例)和研究组(20例)。对照组单独采用肝动脉化疗栓塞术(TACE)治疗,研究组联合采用经导管植入125I放射性粒子治疗。比较两组的近期疗效、不良反应和随访12个月后两组的生存情况。结果研究组的治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。研究组的不良反应发生率明显低于对照组(P<0.05)。研究组在6和12个月内的生存率均明显高于对照组(P<0.05)。结论经导管植入125I放射性粒子治疗肝癌伴门静脉癌栓疗效显著,且不良反应少,可有效提高患者的生存率,值得在临床进行研究和推广。

Objective To investigate the effect of transcatheter implantation of 125I radioactive seeds in the treatment of hepatocellular carcinoma with portal vein cancer thrombus.Methods From March 2016 to March 2018,40 patients with hepatocellular carcinoma and portal vein cancer thrombus in Xiangyaping Collaborative Hospital,Jiangxi Province were selected as the research subjects.They were divided into control group(20 cases)and study group(20 cases)according to different treatment methods.The control group patients were treated by transcatheter arterial chemoembolization(TACE)alone,and the study group was treated with 125I radioactive seeds implanted through catheter.The short-term efficacy,adverse reactions and survival of the two groups after 12 months of follow-up were compared.Results The total effective rate of the study group was significantly higher than that of the control group(P<0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).The survival rate of the study group was significantly higher than that of the control group within 6 and 12 months(P<0.05).Conclusion Transcatheter implantation of 125I radioactive particles in the treatment of hepatocellular carcinoma with portal vein cancer thrombus is effective,with fewer adverse reactions,and can effectively improve the survival rate of patients,which is worthy of further study and promotion in clinical practice.